|
Sign In to gain access to subscriptions and/or personal tools.
|
Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study
C Dostál
Institute of Rheumatology, Prague; first Medical Faculty, Charles University Prague; Czech Republic
V Tesa
I Rychlík
J Zabka
First Internal Clinic, first Medical Faculty, Charles University Prague; Czech Republic
J Vencovsk
Institute of Rheumatology, Prague; first Medical Faculty, Charles University Prague; Czech Republic
J Bartû ková
First Internal Clinic, first Medical Faculty, Charles University Prague; Czech Republic
A Stejskalová
Hlava's Institute of Pathology, First Medical Faculty, Charles University Prague, Czech Republic
D Tegzova
Institute of Rheumatology, Prague; first Medical Faculty, Charles University Prague; Czech Republic
Our objective was to determine the effect of 1 year low-dose cyclosporine A (CSA) treatment on disease activity and renal involvement in systemic lupus erythematosus (SLE). Patients included in the pilot study had an active form of the disease as defined by the SLE Disease Activity Index (SLEDAI). Main organ involvement was represented by lupus nephritis classified in repeated renal biopsies. Eleven patients with SLE were enrolled in the study. In eight of them, previous therapy with cyclophosphamide or azathioprine had to be interrupted due to serious adverse reaction or low efficacy. Nine patients experienced clinical nephrotic syndrome, and two the nephritic syndrome. After 12 months of CSA treatment, the mean SLEDAI score had decreased significantly from 26.18 to 4.00 (P < 0.01). Similarly, the titre of antinuclear and anti-dsDNA antibodies had dropped significantly (P < 0.01). Proteinuria decreased rapidly from 9.10 to 1.70 g/24 h (P < 0.001). According to the WHO classification of renal biopsies, three patients had their class altered from IV to III in response to CSA treatment and five patients had changed the status from the high severity grade to the mild. The adverse reactions included hypertension (45%), gingival hyperplasia (18%) and hirsutism (9%). No significant increase in serum creatinine or any CSA related toxic changes were found in renal biopsies. The favourable response observed in patients with active SLE and with major renal involvement strongly suggests that low-dose CSA is a potent drug as much for the reduction of the disease activity as for lupus nephropathy treatment.
Key Words: lupus nephropathy • treatment • cyclosporine A
Lupus, Vol. 7, No. 1,
29-36 (1998)
DOI: 10.1191/096120398678919714
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Puigmule, J. Lopez-Hellin, G. Sune, O. Tornavaca, S. Camano, A. Tejedor, and A. Meseguer
Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells
Nephrol. Dial. Transplant.,
September 1, 2009;
24(9):
2672 - 2686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Moroni, A. Doria, and C. Ponticelli
Cyclosporine (CsA) in lupus nephritis: assessing the evidence
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
15 - 20.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Baca, T Catalan, M Villasis-Keever, G Ramon, A. Morales, and F Rodriguez-Leyva
Effect of Low-Dose Cyclosporine A in the Treatment of Refractory Proteinuria in Childhood-Onset Lupus Nephritis
Lupus,
August 1, 2006;
15(8):
490 - 495.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Mosca, R Neri, S Giannessi, A Pasquariello, R Puccini, W Bencivelli, and S Bombardieri
Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis
Lupus,
April 1, 2001;
10(4):
253 - 257.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B Griffiths and P Emery
The treatment of lupus with cyclosporin A
Lupus,
March 1, 2001;
10(3):
165 - 170.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Conti, R Priori, C Alessandri, F R Spinelli, E Medda, and G Valesini
Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A
Lupus,
November 1, 2000;
9(9):
676 - 680.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. L. Bick
Recurrent Miscarriage Syndrome due to Blood Coagulation Protein/Platelet Defects: Prevalence, Treatment and Outcome Results
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2000;
6(3):
115 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S J Morton and R J Powell
An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use
Ann Rheum Dis,
June 1, 2000;
59(6):
487 - 489.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D Hallegua, D J Wallace, A L Metzger, R Z Rinaldi, and J R Klinenberg
Cyclosporine for lupus membranous nephritis:experience with ten patients and review of the literature
Lupus,
May 1, 2000;
9(4):
241 - 251.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. DAVID-NETO, F. B. C. LEMOS, E. ARAI FURUSAWA, B. S. SCHWARTZMAN, J. S. CAVALCANTE, E. M. YAGYU, P. ROMANO, and L. E. IANHEZ
Impact of Cyclosporin A Pharmacokinetics on the Presence of Side Effects in Pediatric Renal Transplantation
J. Am. Soc. Nephrol.,
February 1, 2000;
11(2):
343 - 349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gaubitz, A. Schorat, H. Schottel, P. Kern, and W. Domschke
Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial
Lupus,
November 1, 1999;
8(9):
731 - 736.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y Sherer, P Langevitz, Y Levy, F Fabrizzi, and Y Shoenfeld
Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin
Lupus,
May 1, 1999;
8(4):
324 - 327.
[Abstract]
[PDF]
|
|
|
|
|
